Stories

The coverage of Marty Makary's resignation highlights media incentives and vaping policy. The narrative focuses on Trump's alleged influence on flavored vape approvals while neglecting data showing declining youth vaping rates and youth smoking during the vaping era. Makary's stance against political pressure was emphasized, overshadowing scientific nuances. The media portrayed any support for flavored vapes as corrupt, ignoring their potential harm reduction benefits. The text raises concerns about media bias and incomplete reporting, urging for a more comprehensive approach to policy decisions, including considering all evidence and complexities. Ignoring conflicting data and focusing on preferred narratives can lead to flawed public health policies.

Growing criticism of the World Health Organization’s position on tobacco harm reduction is now emerging from within its own former leadership. Three former WHO directors argue that achieving major reductions in global smoking prevalence may require greater acceptance of lower-risk nicotine products as part of public health strategy. They warn that excluding harm reduction from tobacco control frameworks could slow progress in reducing smoking-related disease and mortality, particularly in countries where cigarette use remains widespread. The debate reflects broader tensions between abstinence-focused policies and approaches centred on risk reduction, consumer behaviour, and evidence-based regulation.

A recent study on e‑cigarette use and smoking cessation found that using nicotine vapes with support increases quitting success by 2-3 times compared to support alone. Vaping also led to a reduction of 4–5 cigarettes per day. Results varied on whether vapes were more effective than traditional stop‑smoking medicines. Consistent vape usage was crucial for quitting success. High-quality studies confirmed vaping as an effective quit aid, but long-term data and evolving vape products pose some concerns. Overall, the study highlights the importance of integrating vapes into smoking cessation programs and addressing the stigma around their use.

Navigating the complex PMTA process involves years of compiling applications, paying for legal and compliance costs while facing state and local restrictions. Despite declining smoking rates, concerns arise over FDA authorizations, especially in cases like GLAS. Large tobacco companies invest billions in expansions, hinting at foreknowledge of regulatory outcomes. Small businesses are left waiting, contrasting with big corporations' bold moves. Doubts about regulatory coherence lead to skepticism, as concerns about regulatory personnel transitions and industry ties emerge. Uncertainty prevails for small businesses awaiting decisions, while larger corporations seem assured. The system's mixed messages raise questions about fairness and predictability in public health regulation.

Recent survey findings suggest that public attitudes toward nicotine and tobacco policy may be more complex than commonly reflected in advocacy campaigns and media narratives. The data indicate that many smokers feel increasingly stigmatised and disconnected from public health messaging, particularly when harm reduction approaches are excluded from policy discussions. Researchers and analysts argue that overlooking the perspectives and behavioural realities of smokers may limit the effectiveness of tobacco control strategies aimed at reducing combustible cigarette use. The findings also reinforce ongoing debates about the role of consumer choice, risk communication, and access to lower-risk alternatives within evidence-based public health policy.

Achieving a tobacco-free generation may require stronger integration of harm reduction strategies within public health policy. Emerging evidence suggests that restrictive approaches alone are often insufficient to reduce smoking prevalence, particularly among populations with high levels of nicotine dependence. Researchers increasingly argue that access to lower-risk nicotine alternatives, combined with accurate risk communication, could accelerate declines in combustible cigarette use. The findings contribute to a broader debate on how evidence-based regulation can balance prevention goals with pragmatic approaches to reducing smoking-related disease and mortality.

Public understanding of the relative risks of nicotine products appears to be moving further away from current scientific evidence. A growing proportion of smokers now believe that vaping is as harmful as — or even more harmful than — combustible cigarettes, despite multiple studies indicating substantially lower exposure to toxicants in non-combustible products. Researchers warn that these misperceptions may discourage smokers from switching away from cigarettes, which remain the leading cause of tobacco-related disease and death. The findings also highlight the increasing impact of misinformation, media narratives, and risk communication failures on public health behaviour.

Debates around tobacco harm reduction are increasingly exposing tensions between public health messaging and institutional behaviour. Critics argue that some organisations continue to reject lower-risk nicotine alternatives while simultaneously supporting policies that have failed to reduce smoking effectively. The discussion highlights what is seen as a growing disconnect between scientific evidence, consumer experiences and regulatory narratives. Concerns are also raised about selective framing of risk, particularly when safer alternatives are treated similarly to combustible cigarettes. At the centre of the debate lies a broader question of consistency, credibility and whether public health policies are being applied evenly across different forms of nicotine use.

Debates around tobacco harm reduction are increasingly exposing tensions between public health messaging and institutional behaviour. Critics argue that some organisations continue to reject lower-risk nicotine alternatives while simultaneously supporting policies that have failed to reduce smoking effectively. The discussion highlights what is seen as a growing disconnect between scientific evidence, consumer experiences and regulatory narratives. Concerns are also raised about selective framing of risk, particularly when safer alternatives are treated similarly to combustible cigarettes. At the centre of the debate lies a broader question of consistency, credibility and whether public health policies are being applied evenly across different forms of nicotine use.

Ahead of World No Tobacco Day, calls are growing for tobacco and nicotine policies to be guided more consistently by scientific evidence and harm reduction principles. Advocacy groups across the Asia-Pacific region argue that regulation should better distinguish between combustible cigarettes and lower-risk smoke-free alternatives. They contend that policies failing to recognise relative risk may discourage smokers from switching to less harmful products. At the same time, supporters of a science-based approach emphasise the importance of combining youth protection with realistic strategies for reducing smoking-related disease. The debate reflects broader global tensions over how public health policy should respond to evolving nicotine technologies and emerging evidence.